<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Portal hypertensive gastropathy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Portal hypertensive gastropathy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Portal hypertensive gastropathy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Don C Rockey, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy Reau, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 01, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Portal hypertension most commonly develops in the setting of chronic liver injury with cirrhosis and typically is the result of a combination of an increase in resistance to portal blood flow and an increase in portal blood flow. Other less common causes of portal hypertension include noncirrhotic portal hypertension and extrahepatic portal vein thrombosis. (See
         <a class="medical medical_review" href="/z/d/html/90896.html" rel="external">
          "Portal hypertension in adults"
         </a>
         .)
        </p>
        <p>
         Portal hypertension may lead to complications such as the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Variceal hemorrhage
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ascites
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Portal hypertensive gastropathy (PHG)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spontaneous bacterial peritonitis (a complication of ascites)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatic hydrothorax
        </p>
        <p>
        </p>
        <p>
         Portal hypertension may also be associated with several other complications in patients with chronic liver disease, although the pathogenesis of these complications when they are associated with portal hypertension remains unclear.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatorenal syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatopulmonary syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Portopulmonary hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cirrhotic cardiomyopathy
        </p>
        <p>
        </p>
        <p>
         This topic will review the pathogenesis, clinical manifestations, diagnosis, and management of PHG. Other complications of portal hypertension and cirrhosis are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/90896.html" rel="external">
          "Portal hypertension in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">
          "Cirrhosis in adults: Overview of complications, general management, and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H325153004">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Portal hypertensive gastropathy (PHG) has been estimated to occur in 20 to 98 percent of patients with cirrhosis [
         <a href="#rid1">
          1-7
         </a>
         ]. Some of the variability in prevalence estimates may be related to the study of different patient populations and variable definitions of PHG used in different studies. In one of the larger studies that included 1016 patients with severe hepatic fibrosis or cirrhosis who had no prior history of gastrointestinal bleeding, PHG was detected in 37 percent of patients [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         PHG appears to be more common in patients with advanced liver disease, more severe portal hypertension, esophageal varices, or a history of treatment for esophageal varices with sclerotherapy or band ligation [
         <a href="#rid4">
          4-6,8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H60159191">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Portal hypertension is a prerequisite for the development of portal hypertensive gastropathy (PHG). However, the correlation between the severity of portal hypertension and the severity of PHG appears to be weak, and it is unclear as to the relationship between clinically significant portal hypertension and PHG [
         <a href="#rid9">
          9
         </a>
         ]. The pathogenesis of PHG may be related to both congestion and hyperemia in the stomach. This is supported by the finding that gastric mucosal blood flow is increased in patients with cirrhosis and PHG compared with those without PHG [
         <a href="#rid10">
          10
         </a>
         ]. Other possible mechanisms include mucosal ischemia and increased nitric oxide synthase activity or inflammation associated with abnormal blood flow due to portal hypertension, but their etiologic role is uncertain [
         <a href="#rid11">
          11,12
         </a>
         ]. The severity of gastropathy is related to portal pressure, the level of hepatic vascular resistance, and the degree of reduction in hepatic perfusion [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Some studies have suggested that endoscopic sclerotherapy or ligation of esophageal varices increases the risk of developing PHG, though this issue remains controversial [
         <a href="#rid14">
          14
         </a>
         ]. It has been hypothesized that variceal obliteration results in hyperdynamic congestion, which then gives rise to PHG [
         <a href="#rid2">
          2
         </a>
         ]. In a prospective series with 107 patients with portal hypertension from various causes who were studied before and after sclerotherapy [
         <a href="#rid2">
          2
         </a>
         ], PHG was evident in 4 of 35 patients with cirrhosis before sclerotherapy. After sclerotherapy, 21 additional patients (20 percent) developed PHG during a follow-up of 23 months. The risk of developing PHG appeared to be influenced by prior sclerotherapy, the severity of liver disease, the etiology of portal hypertension, and the coexistence of gastric varices, but the risk was not directly correlated with intravariceal pressure.
        </p>
        <p class="headingAnchor" id="H325152467">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with portal hypertensive gastropathy (PHG) are often asymptomatic and are diagnosed when endoscopy is performed for other reasons (eg, to screen for esophageal varices) [
         <a href="#rid15">
          15
         </a>
         ]. However, because the gastric mucosa in the setting of PHG is friable, bleeding may occur when ectatic vessels rupture (though PHG is an uncommon cause of significant bleeding in patients with portal hypertension). When bleeding occurs it is typically chronic, though it can be acute and massive. Patients with chronic bleeding may have occult blood in their stool and/or iron deficiency anemia. Patients with acute bleeding may present with hematemesis, melena, or if the bleeding is massive, hematochezia.
        </p>
        <p>
         Chronic bleeding is estimated to develop in 3 to 60 percent of patients with PHG [
         <a href="#rid3">
          3,4,16,17
         </a>
         ], and acute bleeding is estimated to occur in 2 to 12 percent [
         <a href="#rid3">
          3-5
         </a>
         ]. Among patients with acute bleeding, the majority (90 to 95 percent) have severe PHG [
         <a href="#rid4">
          4,5
         </a>
         ]. (See
         <a class="local">
          'Classification'
         </a>
         below.)
        </p>
        <p>
         The natural history of PHG has been evaluated in prospective studies [
         <a href="#rid3">
          3,4
         </a>
         ]. One study included 315 patients who were followed with clinical and endoscopic examinations every six months for three years [
         <a href="#rid3">
          3
         </a>
         ]. During follow-up, endoscopic PHG remained stable in 29 percent, worsened in 23 percent, improved in 23 percent, and fluctuated in 25 percent. Acute bleeding from PHG was observed in only eight patients (2.5 percent), with one death. Chronic bleeding occurred in 34 patients (11 percent).
        </p>
        <p class="headingAnchor" id="H60159197">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H325153498">
         <span class="h2">
          Diagnostic approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Portal hypertensive gastropathy (PHG) should be suspected in patients with risk factors for portal hypertension who have signs of acute or chronic gastrointestinal bleeding. If PHG is suspected, patients should undergo upper gastrointestinal endoscopy to confirm the diagnosis. PHG should also be suspected in patients with portal hypertension who are undergoing endoscopy for other reasons and have characteristic endoscopic findings (a mosaic-like or "snakeskin" appearance of the gastric mucosa, predominantly in the fundus and body). Mild PHG can be mimicked by a number of other disorders that cause mucosal injury to the stomach. Mucosal biopsies are generally not required but may be helpful if the diagnosis is unclear; however, care should be taken in the setting of coagulopathy. Diagnostic uncertainty most often occurs when gastrointestinal vascular ectasia (GAVE) is also being considered in the differential diagnosis. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H325153671">
         <span class="h2">
          Upper endoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         PHG is typically diagnosed endoscopically. PHG characteristically appears as a fine, white, reticular pattern separating areas of pinkish mucosa, giving the gastric mucosa a snakeskin appearance  (
         <a class="graphic graphic_picture graphicRef105554" href="/z/d/graphic/105554.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid18">
          18
         </a>
         ]. Other findings may include flat or bulging red marks or red spots that resemble vascular ectasias, or black-brown spots [
         <a href="#rid15">
          15
         </a>
         ]. Mucosal changes are usually most evident in the fundus and body (proximal part) of the stomach. In more severe cases, oozing, bleeding, subepithelial hemorrhages, and increased vascularity similar to angiomas are evident, often involving the gastric fundus, gastric body, and antrum.
        </p>
        <p class="headingAnchor" id="H325153492">
         <span class="h2">
          Histologic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Biopsies are generally not needed to make a diagnosis of PHG because the combination of the appropriate clinical setting and endoscopic appearance of the lesion is usually sufficient. If biopsies are obtained because of a suspicion of PHG, care should be taken in the setting of coagulopathy. If biopsies are obtained, typical histologic findings include dilated submucosal and mucosal veins and ectatic capillaries [
         <a href="#rid19">
          19
         </a>
         ]. Findings such as inflammation and thrombi are absent.
        </p>
        <p class="headingAnchor" id="H325153350">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Portal hypertensive gastropathy (PHG) is typically categorized as either mild or severe [
         <a href="#rid15">
          15
         </a>
         ]. Mild PHG is characterized by a mosaic-like pattern without other findings. Severe PHG is characterized by a mosaic-like pattern with flat or bulging red or black-brown spots and/or active bleeding.
        </p>
        <p class="headingAnchor" id="H325152531">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H325153769">
         <span class="h2">
          Chronic bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis for patients with chronic bleeding encompasses different lesions throughout the gastrointestinal tract, including peptic ulcer disease, angiodysplasia, and malignancies  (
         <a class="graphic graphic_table graphicRef103148" href="/z/d/graphic/103148.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid20">
          20
         </a>
         ]. When diffuse mucosal changes are seen on endoscopy, gastritis (often related to drugs or toxins such as alcohol) is a potential source. The evaluation of occult bleeding includes upper endoscopy, colonoscopy, possible evaluation of the small bowel, other testing (such as cross-sectional imaging), and this is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2544.html" rel="external">
          "Evaluation of occult gastrointestinal bleeding"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H325153776">
         <span class="h2">
          Acute bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with risk factors for portal hypertensive gastropathy (PHG) (eg, cirrhosis) may bleed from other upper gastrointestinal tract lesions, especially esophagogastric varices, but also from peptic ulcer disease and esophagitis [
         <a href="#rid21">
          21
         </a>
         ]. Upper endoscopy permits differentiation among these different bleeding sources  (
         <a class="graphic graphic_table graphicRef103148" href="/z/d/graphic/103148.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2644.html" rel="external">
          "Causes of upper gastrointestinal bleeding in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">
          "Approach to acute upper gastrointestinal bleeding in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H325153783">
         <span class="h2">
          Endoscopic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastrointestinal vascular ectasia (GAVE) is also associated with cirrhosis and may be difficult to differentiate from PHG. It is important to differentiate between the two entities because they are treated differently. GAVE is treated with thermoablative therapy, whereas PHG is treated with measures aimed at reducing portal pressure. Findings that favor a diagnosis of GAVE include an antral-predominant location of the lesions and a classic linear pattern of lesions. In situations where the diagnosis remains unclear, histological analysis may be helpful. Histologic findings that suggest GAVE include extensive vascular ectasia, spindle cell proliferation, fibrin thrombi, and fibrohyalinosis [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2644.html" rel="external">
          "Causes of upper gastrointestinal bleeding in adults", section on 'Gastric antral vascular ectasia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H60159209">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H57728536">
         <span class="h2">
          Management overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         An overview of the management of portal hypertensive gastropathy (PHG) is presented in the table  (
         <a class="graphic graphic_table graphicRef103137" href="/z/d/graphic/103137.html" rel="external">
          table 2
         </a>
         ). In general, the management of PHG is directed at decreasing portal pressure [
         <a href="#rid15">
          15
         </a>
         ], and depends on the acuity and severity of bleeding:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary prophylaxis – Primary prophylaxis to prevent bleeding with a nonselective beta blocker may be appropriate in patients with severe PHG or in patients who have other indications for nonselective beta blocker therapy (eg, varices). (See
         <a class="local">
          'Primary prophylaxis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic bleeding – Among patients with chronic bleeding, treatment typically consists of a nonselective beta blocker as well as iron repletion and/or blood transfusions. If medical therapy is successful at controlling the bleeding, secondary prophylaxis with a nonselective beta blocker should be continued indefinitely. (See
         <a class="local">
          'Chronic bleeding'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute bleeding – For patients with acute bleeding, treatment includes administration of a vasoactive medication, resuscitation/blood transfusion as needed, and, for patients with cirrhosis, antibiotic prophylaxis. Once the bleeding is controlled, a nonselective beta blocker is started and continued indefinitely. (See
         <a class="local">
          'Acute bleeding'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">
          "Approach to acute upper gastrointestinal bleeding in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Refractory bleeding – If initial therapy fails and bleeding is severe and refractory, transjugular intrahepatic portosystemic shunt (TIPS) placement or shunt surgery may be considered. Liver transplantation is an option for patients with decompensated liver disease. In patients who fail medical therapy but have less severe bleeding, management with iron repletion and/or blood transfusions is an alternative. (See
         <a class="local">
          'Refractory bleeding'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Nonselective beta blockers include
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         and
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          nadolol
         </a>
         .
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          Carvedilol
         </a>
         is a mixed beta (beta-1 and beta-2) and alpha (alpha-1) adrenergic receptor blocker and has been shown to reduce portal pressure, though it has not been studied specifically with regard to PHG. It appears to be well tolerated and simple to use, and we find it useful in patients who are not able to tolerate propranolol or nadolol. Beta blockers should be titrated to a heart rate of 50 to 55 beats per minute or to the maximum tolerated dose:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          Propranolol
         </a>
         – Starting dose 20 mg orally twice daily; maximum 160 mg twice daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          Nadolol
         </a>
         – Starting dose 40 mg orally once daily; maximum 160 mg once daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          Carvedilol
         </a>
         – Starting dose 3.125 mg orally twice daily; maximum 25 mg twice daily
        </p>
        <p>
        </p>
        <p>
         We generally avoid beta blockers in patients with hypotension (systolic blood pressure &lt;100 mmHg) or with severe ascites. (See
         <a class="medical medical_review" href="/z/d/html/1258.html" rel="external">
          "Ascites in adults with cirrhosis: Diuretic-resistant ascites", section on 'Discontinuing beta blockers'
         </a>
         .)
        </p>
        <p>
         Vasoactive medications include
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         , somatostatin, and
         <a class="drug drug_general" data-topicid="139628" href="/z/d/drug information/139628.html" rel="external">
          terlipressin
         </a>
         , and are given as follows in patients with acute bleeding:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          Octreotide
         </a>
         – 100 mcg intravenous (IV) bolus followed by an IV infusion of 25 mcg/hour for 48 hours.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Somatostatin – 250 mcg IV bolus followed by an IV infusion of 250 mcg/hour for three days.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="139628" href="/z/d/drug information/139628.html" rel="external">
          Terlipressin
         </a>
         (available in the United States; gastrointestinal bleeding is an off-label indication) – 2 mg IV every four hours initially, then titrated down to 1 mg every four hours once bleeding is controlled. It is continued for up to five days.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H325153879">
         <span class="h2">
          Primary prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with mild PHG who do not have signs of bleeding and who do not have esophagogastric varices do not require treatment. On the other hand, patients with severe PHG may benefit from treatments aimed at reducing portal pressure, though high-quality studies in the setting are lacking. We treat patients with severe PHG with a nonselective beta blocker if they have other factors that increase their risk of bleeding (eg, a coagulopathy, thrombocytopenia)  (
         <a class="graphic graphic_table graphicRef103137" href="/z/d/graphic/103137.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Chronic bleeding'
         </a>
         below.)
        </p>
        <p>
         Patients with PHG and small esophageal varices should receive a nonselective beta blocker if there are no contraindications. This is because nonselective beta blockers are generally indicated for primary prophylaxis against variceal hemorrhage in patients with small varices and may also be beneficial for PHG in this setting [
         <a href="#rid8">
          8,23,24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1245.html" rel="external">
          "Primary prevention of bleeding from esophageal varices in patients with cirrhosis", section on 'Selecting a strategy'
         </a>
         .)
        </p>
        <p>
         Options for primary prophylaxis to prevent variceal hemorrhage in patients with medium or large varices include a nonselective beta blocker or endoscopic variceal ligation. Our approach in patients with PHG and medium or large varices is to treat with a nonselective beta blocker because of the potential therapeutic benefit for varices and PHG. We reserve endoscopic therapy for patients who are intolerant of or who have contraindications to beta blocker therapy. This often includes patients with advanced liver disease (Child-Pugh class C).
        </p>
        <p class="headingAnchor" id="H325153906">
         <span class="h2">
          Chronic bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with chronic bleeding, our approach is to start therapy aimed at lowering portal pressure (typically a nonselective beta blocker such as
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          nadolol
         </a>
         [
         <a href="#rid16">
          16,19,25
         </a>
         ], or
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          carvedilol
         </a>
         ), and to replete the patients' iron stores if needed (typically orally, although intravenous iron is also an effective option)  (
         <a class="graphic graphic_table graphicRef103137" href="/z/d/graphic/103137.html" rel="external">
          table 2
         </a>
         ). Patients with a hemoglobin &lt;7 g/dL also typically require blood transfusion. (See
         <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">
          "Treatment of iron deficiency anemia in adults", section on 'Oral iron'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">
          "Treatment of iron deficiency anemia in adults", section on 'Intravenous iron'
         </a>
         .)
        </p>
        <p>
         The use of nonselective beta blockers for patients with bleeding from PHG was examined in a trial with 54 patients with PHG and acute or chronic bleeding from severe PHG [
         <a href="#rid16">
          16
         </a>
         ].
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          Propranolol
         </a>
         reduced the rate of recurrent bleeding compared with placebo (9 of 26 patients [35 percent] versus 17 of 28 patients [62 percent] at one year).
        </p>
        <p class="headingAnchor" id="H325154118">
         <span class="h2">
          Acute bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with acute bleeding should be managed as other patients with acute upper gastrointestinal bleeding (UGIB), including obtaining adequate intravenous access, fluid resuscitation, blood transfusion, starting an intravenous proton pump inhibitor (PPI), and performing early upper endoscopy  (
         <a class="graphic graphic_algorithm graphicRef105093" href="/z/d/graphic/105093.html" rel="external">
          algorithm 1
         </a>
         ). In addition, vasoconstrictor therapy with a medication such as
         <a class="drug drug_general" data-topicid="139628" href="/z/d/drug information/139628.html" rel="external">
          terlipressin
         </a>
         or
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         should be initiated as soon as possible (prior to endoscopy)  (
         <a class="graphic graphic_table graphicRef103137" href="/z/d/graphic/103137.html" rel="external">
          table 2
         </a>
         ). Patients with cirrhosis also require antibiotic prophylaxis. The general approach to patients with UGIB is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">
          "Approach to acute upper gastrointestinal bleeding in adults"
         </a>
         .)
        </p>
        <p>
         If the bleeding is confirmed to be from PHG, the vasoconstrictor should be continued (or started if it was not given initially). The use of PPIs in this setting remains controversial, but because acid is not likely to play a major role in patients with bleeding from PHG, the PPI can be discontinued unless it is indicated for another reason.
        </p>
        <p>
         The efficacy of vasoconstrictors for acute bleeding from PHG was demonstrated in a trial of 68 patients [
         <a href="#rid26">
          26
         </a>
         ]. Patients were assigned to receive
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         ,
         <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">
          vasopressin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         . Bleeding was controlled in all 24 of the patients who received octreotide, in 14 of 22 (64 percent) of the patients who received vasopressin, and in 13 of 22 (59 percent) of patients who received omeprazole. In a second trial with 86 patients with bleeding from PHG or varices, those who received higher doses of
         <a class="drug drug_general" data-topicid="139628" href="/z/d/drug information/139628.html" rel="external">
          terlipressin
         </a>
         had better bleeding control and lower recurrence rates than patients who received lower doses [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Because PHG is a diffuse process, endoscopic therapy is typically not effective. However, endoscopic thermal coagulation may be effective for patients with focally bleeding lesions. Banding, injection therapy, H2 blockers, and topical agents such as
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          sucralfate
         </a>
         are ineffective for controlling diffuse bleeding or for preventing rebleeding from extensive PHG. A case series has described the successful use of hemostatic nanopowder in patients with acute bleeding from PHG [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2573.html" rel="external">
          "Overview of the treatment of bleeding peptic ulcers", section on 'Hemostatic sprays'
         </a>
         .)
        </p>
        <p>
         Once the acute bleeding episode has resolved, the patient should be started on a nonselective beta blocker, as is done for secondary prophylaxis of acute variceal hemorrhage [
         <a href="#rid19">
          19,29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1252.html" rel="external">
          "Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis", section on 'Specific interventions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H325154496">
         <span class="h2">
          Refractory bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most challenging patients with PHG are those who fail to respond to initial pharmacologic therapy. Alternative and additional treatment options include TIPS placement, shunt surgery, and liver transplantation  (
         <a class="graphic graphic_table graphicRef103137" href="/z/d/graphic/103137.html" rel="external">
          table 2
         </a>
         ). The choice of therapy will depend on local expertise with TIPS placement and surgical shunting and whether the patient is a candidate for liver transplantation. However, not all patients with refractory bleeding will require such invasive intervention. Patients with less severe chronic bleeding may be adequately managed with iron repletion and/or blood transfusion. (See
         <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">
          "Treatment of iron deficiency anemia in adults"
         </a>
         .)
        </p>
        <p>
         Information on the efficacy of TIPS placement for PHG is limited. In one series involving 40 patients, TIPS placement was associated with an improvement in endoscopic findings and a decrease in transfusion requirement in 89 and 75 percent of patients with mild and severe PHG, respectively [
         <a href="#rid30">
          30
         </a>
         ]. Endoscopic improvement in patients with mild PHG was visible within six weeks in most patients and by three to six months in approximately 85 percent of patients. The response was slower in patients with severe PHG.
        </p>
        <p class="headingAnchor" id="H2650392319">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114134.html" rel="external">
          "Society guideline links: Gastrointestinal bleeding in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114698.html" rel="external">
          "Society guideline links: Portal hypertension and ascites"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology –
         </strong>
         Portal hypertensive gastropathy (PHG) is estimated to occur in 20 to 98 percent of patients with cirrhosis. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features –
         </strong>
         Patients with PHG are often asymptomatic and are diagnosed when endoscopy is performed for other reasons (eg, to screen for esophageal varices). Bleeding is typically chronic, though it can be acute and massive in some patients. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis –
         </strong>
         PHG should be suspected in patients with risk factors for portal hypertension who have symptoms and/or signs of acute or chronic gastrointestinal bleeding (UGIB). Patients with evidence of UGIB should undergo upper GI endoscopy to confirm the diagnosis. PHG should also be suspected in patients with portal hypertension who are undergoing endoscopy for other reasons and have characteristic endoscopic findings (a mosaic-like or "snakeskin" appearance of the gastric mucosa, especially in the cardia, fundus, and/or body). Biopsies may be required if the diagnosis is unclear (especially if gastric antral vascular ectasia is also being considered in the differential diagnosis). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification –
         </strong>
         PHG is most commonly categorized endoscopically as either mild or severe. Mild PHG is characterized by a mosaic-like pattern without other findings. Severe PHG is characterized by a mosaic-like pattern with flat or bulging red or black-brown spots, or by active hemorrhage. (See
         <a class="local">
          'Classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management –
         </strong>
         The goal of management of PHG is to reduce portal pressure  (
         <a class="graphic graphic_table graphicRef103137" href="/z/d/graphic/103137.html" rel="external">
          table 2
         </a>
         ). The specific approach depends on the acuity and severity of bleeding (see
         <a class="local">
          'Management'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Primary prophylaxis
         </strong>
         – In patients with severe PHG and other risk factors for GI bleeding (eg, a coagulopathy, thrombocytopenia), we suggest primary prophylaxis with a nonselective beta blocker rather than giving no prophylaxis (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Nonselective beta blockers should also be started in patients who have other indications for nonselective beta blocker therapy (eg, varices).
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          Carvedilol
         </a>
         is an alternative for patients who cannot take beta blockers or do not tolerate them. For all other patients, we suggest
         <strong>
          not
         </strong>
         giving primary prophylaxis (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Primary prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chronic bleeding
         </strong>
         – Patients with chronic bleeding should receive iron repletion/blood transfusions as needed. In addition, we suggest that patients with chronic bleeding also receive treatment with a nonselective beta blocker rather than treatment with iron repletion/blood transfusions alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          Carvedilol
         </a>
         is an alternative for patients who cannot take beta blockers or do not tolerate them. If medical therapy is successful at controlling the bleeding, the medication should be continued indefinitely. (See
         <a class="local">
          'Chronic bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute bleeding
         </strong>
         – Patients with acute bleeding should be managed the same as patients with other causes of UGIB. Management includes resuscitation/blood transfusion as necessary, upper endoscopy, and, for patients with cirrhosis, antibiotic prophylaxis. For patients known to have PHG, we suggest additional treatment with a vasoactive medication (eg,
         <a class="drug drug_general" data-topicid="139628" href="/z/d/drug information/139628.html" rel="external">
          terlipressin
         </a>
         or
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         ) rather than supportive measures alone (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). This suggestion is based both on studies that have examined the use of vasoactive medications in patients with acute bleeding from PHG as well as the efficacy of vasoactive medications in patients with bleeding from other complications of portal hypertension. Vasoactive medications should also be given to patients with known or suspected varices. Once bleeding is controlled, a nonselective beta blocker is started and continued indefinitely. (See
         <a class="local">
          'Acute bleeding'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">
          "Approach to acute upper gastrointestinal bleeding in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1260.html" rel="external">
          "Methods to achieve hemostasis in patients with acute variceal hemorrhage", section on 'Pharmacologic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Refractory bleeding
         </strong>
         – For patients who fail to respond to initial therapy, further treatment options include transjugular intrahepatic portosystemic shunt (TIPS) placement, shunt surgery, and liver transplantation. The choice of therapy will depend on local expertise with TIPS placement and surgical shunting and whether the patient is a liver transplant candidate. However, not all patients with refractory bleeding will require invasive treatment. Patients with less severe chronic bleeding may be adequately managed with iron repletion and/or blood transfusion. (See
         <a class="local">
          'Refractory bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Fontana RJ, Sanyal AJ, Mehta S, et al. Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol 2006; 101:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarin SK, Sreenivas DV, Lahoti D, Saraya A. Factors influencing development of portal hypertensive gastropathy in patients with portal hypertension. Gastroenterology 1992; 102:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Primignani M, Carpinelli L, Preatoni P, et al. Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. The New Italian Endoscopic Club for the study and treatment of esophageal varices (NIEC). Gastroenterology 2000; 119:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merli M, Nicolini G, Angeloni S, et al. The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension. Am J Gastroenterol 2004; 99:1959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Amico G, Montalbano L, Traina M, et al. Natural history of congestive gastropathy in cirrhosis. The Liver Study Group of V. Cervello Hospital. Gastroenterology 1990; 99:1558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwao T, Toyonaga A, Oho K, et al. Portal-hypertensive gastropathy develops less in patients with cirrhosis and fundal varices. J Hepatol 1997; 26:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thuluvath PJ, Yoo HY. Portal Hypertensive gastropathy. Am J Gastroenterol 2002; 97:2973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cubillas R, Rockey DC. Portal hypertensive gastropathy: a review. Liver Int 2010; 30:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marrache MK, Bou Daher H, Rockey DC. The relationship between portal hypertension and portal hypertensive gastropathy. Scand J Gastroenterol 2022; 57:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohta M, Hashizume M, Higashi H, et al. Portal and gastric mucosal hemodynamics in cirrhotic patients with portal-hypertensive gastropathy. Hepatology 1994; 20:1432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Newihi HM, Kanji VK, Mihas AA. Activity of gastric mucosal nitric oxide synthase in portal hypertensive gastropathy. Am J Gastroenterol 1996; 91:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piasecki C, Chin J, Greenslade L, et al. Endoscopic detection of ischaemia with a new probe indicates low oxygenation of gastric epithelium in portal hypertensive gastropathy. Gut 1995; 36:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwao T, Toyonaga A, Sumino M, et al. Portal hypertensive gastropathy in patients with cirrhosis. Gastroenterology 1992; 102:2060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hou MC, Lin HC, Kuo BI, et al. Comparison of endoscopic variceal injection sclerotherapy and ligation for the treatment of esophageal variceal hemorrhage: a prospective randomized trial. Hepatology 1995; 21:1517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urrunaga NH, Rockey DC. Portal hypertensive gastropathy and colopathy. Clin Liver Dis 2014; 18:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-Ayuso RM, Piqué JM, Bosch J, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 1991; 337:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarin SK, Shahi HM, Jain M, et al. The natural history of portal hypertensive gastropathy: influence of variceal eradication. Am J Gastroenterol 2000; 95:2888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wollenman CS, Chason R, Reisch JS, Rockey DC. Impact of ethnicity in upper gastrointestinal hemorrhage. J Clin Gastroenterol 2014; 48:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patwardhan VR, Cardenas A. Review article: the management of portal hypertensive gastropathy and gastric antral vascular ectasia in cirrhosis. Aliment Pharmacol Ther 2014; 40:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rockey DC. Occult and obscure gastrointestinal bleeding: causes and clinical management. Nat Rev Gastroenterol Hepatol 2010; 7:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyles T, Elliott A, Rockey DC. A risk scoring system to predict in-hospital mortality in patients with cirrhosis presenting with upper gastrointestinal bleeding. J Clin Gastroenterol 2014; 48:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Payen JL, Calès P, Voigt JJ, et al. Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis. Gastroenterology 1995; 108:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004; 127:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhardwaj A, Kedarisetty CK, Vashishtha C, et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. Gut 2017; 66:1838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rockey DC. An Update: Portal Hypertensive Gastropathy and Colopathy. Clin Liver Dis 2019; 23:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou Y, Qiao L, Wu J, et al. Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study. J Gastroenterol Hepatol 2002; 17:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruha R, Marecek Z, Spicak J, et al. Double-blind randomized, comparative multicenter study of the effect of terlipressin in the treatment of acute esophageal variceal and/or hypertensive gastropathy bleeding. Hepatogastroenterology 2002; 49:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith LA, Morris AJ, Stanley AJ. The use of hemospray in portal hypertensive bleeding; a case series. J Hepatol 2014; 60:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022; 76:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamath PS, Lacerda M, Ahlquist DA, et al. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology 2000; 118:905.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2645 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16573786" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1537536" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Factors influencing development of portal hypertensive gastropathy in patients with portal hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10889167" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. The New Italian Endoscopic Club for the study and treatment of esophageal varices (NIEC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15447756" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2227271" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Natural history of congestive gastropathy in cirrhosis. The Liver Study Group of V. Cervello Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9210609" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Portal-hypertensive gastropathy develops less in patients with cirrhosis and fundal varices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12492178" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Portal Hypertensive gastropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20536720" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Portal hypertensive gastropathy: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34904513" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The relationship between portal hypertension and portal hypertensive gastropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7982641" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Portal and gastric mucosal hemodynamics in cirrhotic patients with portal-hypertensive gastropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8633504" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Activity of gastric mucosal nitric oxide synthase in portal hypertensive gastropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7797112" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Endoscopic detection of ischaemia with a new probe indicates low oxygenation of gastric epithelium in portal hypertensive gastropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1587424" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Portal hypertensive gastropathy in patients with cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7768494" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Comparison of endoscopic variceal injection sclerotherapy and ligation for the treatment of esophageal variceal hemorrhage: a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24679502" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Portal hypertensive gastropathy and colopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1675316" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11051364" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The natural history of portal hypertensive gastropathy: influence of variceal eradication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24275716" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Impact of ethnicity in upper gastrointestinal hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24889902" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Review article: the management of portal hypertensive gastropathy and gastric antral vascular ectasia in cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20351759" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Occult and obscure gastrointestinal bleeding: causes and clinical management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24172184" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A risk scoring system to predict in-hospital mortality in patients with cirrhosis presenting with upper gastrointestinal bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7806035" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15300580" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27298379" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31563216" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : An Update: Portal Hypertensive Gastropathy and Colopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12167118" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12143227" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Double-blind randomized, comparative multicenter study of the effect of terlipressin in the treatment of acute esophageal variceal and/or hypertensive gastropathy bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24140803" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The use of hemospray in portal hypertensive bleeding; a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35120736" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Baveno VII - Renewing consensus in portal hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10784589" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
